<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745119</url>
  </required_header>
  <id_info>
    <org_study_id>GX30191</org_study_id>
    <secondary_id>2016-000423-13</secondary_id>
    <nct_id>NCT02745119</nct_id>
  </id_info>
  <brief_title>Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)</brief_title>
  <official_title>A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter open-label extension study is designed to evaluate the safety and
      tolerability of lampalizumab intravitreal injections in participants with GA secondary to
      age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176
      (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the
      parent studies who received investigational lampalizumab, as well as lampalizumab-naive
      participants exposed to sham comparator. All participants will receive open-label
      lampalizumab in the present study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 21, 2016</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Ocular Adverse Events (AEs) by Severity</measure>
    <time_frame>Up to approximately one year</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are the events which are localized in the ocular region.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Systemic (Non-Ocular) AEs by Severity</measure>
    <time_frame>Up to approximately one year</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Anti-Lampalizumab Antibodies</measure>
    <time_frame>Week 48</time_frame>
    <description>The immunogenicity analysis included participants with at least one predose and one postdose anti-lampalizumab antibodies assessment. Predose was defined as prior to the first dose in the extension study for the prior sham participants, and prior to the first dose in the parent study for the prior lampalizumab participants.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">994</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>Lampalizumab Every 4 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lampalizumab Every 6 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lampalizumab</intervention_name>
    <description>Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.</description>
    <arm_group_label>Lampalizumab Every 4 Weeks</arm_group_label>
    <arm_group_label>Lampalizumab Every 6 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous enrollment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531) with
             completion of treatment and the Week 96 visit

          -  Agreement to remain abstinent or use a reliable form of contraception among all men
             and among women of child-bearing potential

        Exclusion Criteria:

          -  Concurrent ocular conditions that contraindicate use of lampalizumab or might affect
             interpretation of study results or that might increase the risk of treatment
             complications

          -  Concurrent disease, metabolic dysfunction, or physical or laboratory finding that
             contraindicates use of lampalizumab or might affect interpretation of study results or
             that might increase the risk of treatment complications

          -  Increased risk of infection

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uni of Alabama At Birmingham Clinical Research Unit</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Centers P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates Southwest PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Shiley Eye Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute/ UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N CA Retina Vitreous Assoc</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Retina Consultants</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern CA Desert Retina Cons</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byers Eye Insitute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis, Eye Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Med Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W Coast Retina Med Group Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Ctr; Ophthalmology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Med Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates, PC</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Inst</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Health Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Eye Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Care Specialists</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Lauderdale Eye Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Assoc of FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Vitreoretinal Assoc</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Florida, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute Northside</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo Retinal Consultants</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Med Ctr</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Eye Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates, PC</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Institute</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assoc Retinal Consultants PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Michigan</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifelong Vision Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina - Wills Eye Hospital</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Retina Research Foundation</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>8820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Retina Assoc</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal &amp; Ophthalmic Cons PC</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of NJ</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Is. Vitreoretinal Consult</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthalmic Consultants of LI</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye &amp; Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreous-Retina-Macula</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Assoc of Western NY</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vit Surgeons/Central NY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Carolina Retinal AssocPA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Char Eye Ear &amp;Throat Assoc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center; Vitreoretinal</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Eye Centre</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Assoc of Cleveland Inc</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation; Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Eye Physicians &amp; Surgeons</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina &amp; Vitreous Center of Southern Oregon</name>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <zip>97520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon HSU; Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Ophthalmology</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Neuroscience Inst</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institution</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina PC.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Res Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute P.A.</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategic Clinical Research Group, LLC</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Virginia Ophthalmology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Richmond Inc. dba Virginia Eye Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Retina Center</name>
      <address>
        <city>Warrenton</city>
        <state>Virginia</state>
        <zip>20186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Associates of Washington</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center Northwest</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyeclinic Albury Wodonga</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marsden Eye Research Centre</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Save Sight Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney West Retina</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Eye Institute Eastern</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Augenheilkunde</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und Optometrie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann (Victor Horta)</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Sint Rafael</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut De L'Oeil Des Laurentides</name>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <zip>J7H 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital, Øjenafdelingen, Forskningsafsnit Ø37</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Roskilde; Øjenafdelingen</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin; Ophtalmologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi De Creteil; Ophtalmologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Monticelli Paradis d Ophtalmologie</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu; Ophthalmology</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Odeon; Exploration Ophtalmologique</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHNO des Quinze Vingts; Ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Augenheilkunde</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Augenheilkunde</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg; Augenklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln; Augenklinik</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH; Augenklinik</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniikum Schleswig-Holstein, Campus Lübeck, Klinik für Augenheilkunde</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität, Augenklinik</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München; Augenklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenabteilung am St. Franziskus-Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster; Augenheilkunde</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik &amp; Poliklinik für Augenheilkunde</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem AOK, Szemeszeti Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest Retina Associates Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont, Szemeszet KR</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont; Szemeszeti Klinika</name>
      <address>
        <city>Debrecem</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganglion Medial Center</name>
      <address>
        <city>Pecs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ptv Policlinico Tor Vergata Di Roma;U.O.S.D. Patologie Renitiche</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITA' DEGLI STUDI DI GENOVA - Di.N.O.G.;CLINICA OCULISTICA</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale San Raffaele;U.O. Oculistica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST FATEBENEFRATELLI SACCO; Oculistica (Sacco)</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.L. to1 Presidio Ospedaliero Sperino Oftalmico</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine; Clinica Oculistica</name>
      <address>
        <city>Udine</city>
        <state>Veneto</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TG Laser Oftalmica</name>
      <address>
        <city>Lima</city>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OFTALMIKA Sp. z o.o</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny nr 1; Oddzial Okulistyki</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimum Profesorskie Centrum Okulistyki</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Okulistyczny Prof Edward Wylegala</name>
      <address>
        <city>Katowice</city>
        <zip>40-594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny; Klinika Okulistyki</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Okulistyczna Jasne Błonia</name>
      <address>
        <city>Łódź</city>
        <zip>91-134</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIBILI - Association for Innovation and Biomedical Research on Light</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espaco Medico Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-163</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Oftalmologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica sv. Michala, a.s.</name>
      <address>
        <city>Bratislava</city>
        <zip>81108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, Nemocnica sv. Cyrila a Metoda Ocna klinika SZU a UNB</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica Trencin Ocna klinika</name>
      <address>
        <city>Trencin</city>
        <zip>911 71</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge; Servicio de Oftalmologia</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Quirurgico de Oftalmologia - ICQO</name>
      <address>
        <city>Bilbao</city>
        <state>Guipuzcoa</state>
        <zip>48006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmologico Gomez Ulla</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de Oftalmologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Perpetuo Socorro; Servicio de Oftalmología</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de la Macula i la retina</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de microcirugia ocular</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISSUM Madrid Santa Hortensia</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FISABIO. Fundación Oftalmologica del Mediterraneo</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega; Servicio de Oftalmologia</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern, Universitätsklinik für Augenheilkunde</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Klinik Binningen</name>
      <address>
        <city>Binningen</city>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli; Augenklinik</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Ankara Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucestershire</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital; St Paul's Clinical Eye Research Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macular Treatment Centre; Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton Hospitals NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The York Hospital</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <results_first_submitted>January 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <disposition_first_submitted>August 16, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 21, 2018</disposition_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02745119/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>994 participants enrolled in study . study terminated early by Sponsor due to lack of efficacy.
842 patients received at least one lampalizumab injection 152 patients enrolled in Study GX30191 did not receive study drug in the extension study and thus were excluded from the safety-evaluable population.</recruitment_details>
      <pre_assignment_details>Eligible participants were those who enrolled in Studies GX29176 (NCT02247479) and GX29185 (NCT02247531) and had completed the 96-week treatment period without early treatment discontinuation or study discontinuation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lampalizumab Q4W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Lampalizumab Q4W – Previously Treated</title>
          <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Lampalizumab Q6W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Lampalizumab Q6W – Previously Treated</title>
          <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="277"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</population>
      <group_list>
        <group group_id="B1">
          <title>Lampalizumab Q4W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Lampalizumab Q4W – Previously Treated</title>
          <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Lampalizumab Q6W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Lampalizumab Q6W – Previously Treated</title>
          <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="146"/>
            <count group_id="B4" value="277"/>
            <count group_id="B5" value="842"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.0" spread="8.2"/>
                    <measurement group_id="B2" value="78.7" spread="7.8"/>
                    <measurement group_id="B3" value="79.2" spread="8.6"/>
                    <measurement group_id="B4" value="80.2" spread="7.9"/>
                    <measurement group_id="B5" value="79.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="164"/>
                    <measurement group_id="B5" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="272"/>
                    <measurement group_id="B5" value="827"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="263"/>
                    <measurement group_id="B5" value="810"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Ocular Adverse Events (AEs) by Severity</title>
        <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are the events which are localized in the ocular region.</description>
        <time_frame>Up to approximately one year</time_frame>
        <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lampalizumab Q4W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lampalizumab Q4W – Previously Treated</title>
            <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Lampalizumab Q6W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lampalizumab Q6W – Previously Treated</title>
            <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>All Participants</title>
            <description>All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Ocular Adverse Events (AEs) by Severity</title>
          <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are the events which are localized in the ocular region.</description>
          <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="277"/>
                <count group_id="O5" value="842"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="40.1"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="33.2"/>
                    <measurement group_id="O5" value="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="26.6"/>
                    <measurement group_id="O3" value="16.4"/>
                    <measurement group_id="O4" value="21.7"/>
                    <measurement group_id="O5" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="10.1"/>
                    <measurement group_id="O5" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Systemic (Non-Ocular) AEs by Severity</title>
        <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test.</description>
        <time_frame>Up to approximately one year</time_frame>
        <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lampalizumab Q4W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lampalizumab Q4W – Previously Treated</title>
            <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Lampalizumab Q6W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lampalizumab Q6W – Previously Treated</title>
            <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>All Participants</title>
            <description>All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Systemic (Non-Ocular) AEs by Severity</title>
          <description>An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test.</description>
          <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="277"/>
                <count group_id="O5" value="842"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="54.0"/>
                    <measurement group_id="O3" value="41.8"/>
                    <measurement group_id="O4" value="51.3"/>
                    <measurement group_id="O5" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="20.1"/>
                    <measurement group_id="O3" value="17.8"/>
                    <measurement group_id="O4" value="20.9"/>
                    <measurement group_id="O5" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="20.2"/>
                    <measurement group_id="O5" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="13.5"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="10.1"/>
                    <measurement group_id="O5" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Anti-Lampalizumab Antibodies</title>
        <description>The immunogenicity analysis included participants with at least one predose and one postdose anti-lampalizumab antibodies assessment. Predose was defined as prior to the first dose in the extension study for the prior sham participants, and prior to the first dose in the parent study for the prior lampalizumab participants.</description>
        <time_frame>Week 48</time_frame>
        <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study. Data is reported for evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Lampalizumab Q4W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lampalizumab Q4W – Previously Treated</title>
            <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Lampalizumab Q6W - Treatment-Naive</title>
            <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lampalizumab Q6W – Previously Treated</title>
            <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>All Participants</title>
            <description>All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Lampalizumab Antibodies</title>
          <description>The immunogenicity analysis included participants with at least one predose and one postdose anti-lampalizumab antibodies assessment. Predose was defined as prior to the first dose in the extension study for the prior sham participants, and prior to the first dose in the parent study for the prior lampalizumab participants.</description>
          <population>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study. Data is reported for evaluable participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="277"/>
                <count group_id="O5" value="842"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately one year</time_frame>
      <desc>The safety-evaluable population included all participants who enrolled in the extension study and received at least one lampalizumab injection in the extension study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lampalizumab Q4W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 milligrams (mg), by intravitreal (ITV) injection, administered every 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Lampalizumab Q4W – Previously Treated</title>
          <description>Participants who received lampalizumab every 4 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Lampalizumab Q6W - Treatment-Naive</title>
          <description>Participants who received sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Lampalizumab Q6W – Previously Treated</title>
          <description>Participants who received lampalizumab every 6 weeks in one of the parent studies and completed the Week 96 visit received lampalizumab, 10 mg, by ITV injection, administered every 6 weeks.</description>
        </group>
        <group group_id="E5">
          <title>All Participants</title>
          <description>All participants in the study received lampalizumab 10 mg, ITV, Q4W or Q6W.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="153" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Dellen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Dry age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Central nervous system infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Dementia with lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="186" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="842"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="277"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="842"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early by the Sponsor because the compound had demonstrated lack of efficacy. Thus, no participant in this study completed the full duration of treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>616878333 ext +41</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

